<DOC>
	<DOCNO>NCT02200406</DOCNO>
	<brief_summary>Background : Although substitution therapy show highly effective retain opioid-dependent patient treatment reduce drug use , population afflict numerous condition include depression . Unfortunately , study publish thus far reported inconsistent difference response placebo therapy antidepressant selective serotonin reuptake inhibitor . Objective : To assess feasibility Desvenlafaxine ( DESV ) administration among opioid-dependent subject explore effect depressive symptom . Methods : Open-label pilot trial 8 week DESV 50-100 mg/day 20 methadone-maintained individual comorbid depressive symptom Centre hospitalier de l'Université de Montréal . Significance : This pilot study lay foundation large multisite clinical trial could conduct examine DESV new treatment opioid-dependent population comorbid depression .</brief_summary>
	<brief_title>Desvenlafaxine Opioid-Dependent Patients</brief_title>
	<detailed_description>To assess feasibility , tolerability acceptability 8 week Desvenlafaxine ( DESV ) administration among opioid-dependent subject methadone-maintenance program , collect detailed information compliance DESV treatment , side effect , methadone plasma level , methadone dose change QTc measure . To explore effect DESV depressive symptom among opioid-dependent subject methadone-maintenance treatment . The severity symptoms depression evaluate use MADRS , HRDS , CGI scale . To explore effect DESV substance use , anxiety , craving , quality life suicidal risk .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<mesh_term>Desvenlafaxine Succinate</mesh_term>
	<criteria>DSMIVTR criterion opioid dependence ; Subject methadone treatment substitution program least 4 week ; Subject age 18 65 year old ; subject meet DSMV TR criterion major depressive episode , accord study psychiatrist confirm Mini International Neuropsychiatric Interview ( MINI ) ; Subject report score 20 high MADRS ; Subject eligible consent study ; subject able give valid , informed consent ; subject able speak read French English ( gradenine level language require ) Unstable medical illness , define medical illness wellcontrolled standardofcare medication ; Severe psychiatric condition ( e.g. , current acute psychosis , past current hypomania/mania ) base MINI ; Pregnancy breastfeeding ; Inability use medically acceptable form contraception throughout study duration . A medically acceptable form contraception either : ( 1 ) contraceptive pill intrauterine device depot hormonal preparation ( ring , injection , implant ) ; and/or ( 2 ) barrier method contraception diaphragm , sponge spermicide condom ; Subject currently take another antidepressant ; Treatment Desvenlafaxine time past ; Known hypersensitivity venlafaxine ; Subject undergo psychotherapy current depression ( support therapy counseling allow ) ; Subject fail respond two HealthCanadaapproved antidepressant current episode ; Unstable AxisII personality disorder AxisII disorder primary focus treatment past 3 month , ascertain study psychiatrist ; Medical diagnosis kidney and/or liver failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Desvenlafaxine</keyword>
	<keyword>Opioid-dependent</keyword>
	<keyword>Addiction</keyword>
	<keyword>Depression</keyword>
	<keyword>Methadone</keyword>
	<keyword>Comorbidity</keyword>
</DOC>